Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 32888452

Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
Lancet Oncol
Publication date
2020 Sep
First author
Al-Sawaf O

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet Oncol. 2020 Sep;21(9):1128-1130. doi: 10.1016/S1470-2045(20)30484-8.
    note
    Source null
    related pmid
    32888445
    relationship
    Comment in

Authors and identifiers

  1. name
    Al-Sawaf O
    type
    Author
  2. name
    Zhang C
    type
    Author
  3. name
    Tandon M
    type
    Author
  4. name
    Sinha A
    type
    Author
  5. name
    Fink AM
    type
    Author
  6. name
    Robrecht S
    type
    Author
  7. name
    Samoylova O
    type
    Author
  8. name
    Liberati AM
    type
    Author
  9. name
    Pinilla-Ibarz J
    type
    Author
  10. name
    Opat S
    type
    Author
  11. name
    Sivcheva L
    type
    Author
  12. name
    Le Dû K
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Al-Sawaf O
    type
    Author
  2. name
    Zhang C
    type
    Author
  3. name
    Tandon M
    type
    Author
  4. name
    Sinha A
    type
    Author
  5. name
    Fink AM
    type
    Author
  6. name
    Robrecht S
    type
    Author
  7. name
    Samoylova O
    type
    Author
  8. name
    Liberati AM
    type
    Author
  9. name
    Pinilla-Ibarz J
    type
    Author
  10. name
    Opat S
    type
    Author
  11. name
    Sivcheva L
    type
    Author
  12. name
    Le Dû K
    type
    Author
bibliography ids
    book metadata
    content sha256
    a43d554bf1fb3b1e4d2c75e4fcbb6a908f95a3d264d769291a9d4d9ced70eb9c
    document type
    citation
    dois
    1. 10.1016/S1470-2045(20)30443-5
    electronic publication date
    display
    Source null
    precision
    missing
    year
    Source null
    evidence scope
    bibliographic_metadata_only
    id
    pubmed:32888452
    immutable id
    pubmed:32888452@a43d554bf1fb3b1e4d2c75e4fcbb6a908f95a3d264d769291a9d4d9ced70eb9c
    journal
    abbreviation
    Lancet Oncol
    issn electronic
    1474-5488
    issn print
    1470-2045
    issue
    9
    name
    The Lancet. Oncology
    nlm unique id
    100957246
    pages
    1188-1200
    volume
    21
    languages
    1. eng
    notices
    absence is not clearance
    true
    has correction metadata
    false
    has expression of concern metadata
    false
    has retraction in link
    false
    pubmed marks article retracted
    false
    pubmed marks retraction notice
    false
    relationships
    1. citation
      Lancet Oncol. 2020 Sep;21(9):1128-1130. doi: 10.1016/S1470-2045(20)30484-8.
      note
      Source null
      related pmid
      32888445
      relationship
      Comment in
    outcomes validated
    false
    pmid
    32888452
    provenance
    batch id
    supplemental-32888452-25e669c7eda3
    provider
    NCBI PubMed ESummary
    record sha256
    570b2bf80ca63c21cdb31b05440a0e7057fbdff5038e89f41d46ecfb9ae77deb
    response sha256
    25e669c7eda3f9d47355458e87b6ca51528c670bf528bb71708be6423774fa29
    retrieved at
    2026-09-10T00:01:02.396833+00:00
    publication date
    display
    2020 Sep
    precision
    month
    year
    2020
    publication types
    1. Clinical Trial, Phase III
    2. Journal Article
    3. Multicenter Study
    4. Randomized Controlled Trial
    5. Research Support, Non-U.S. Gov't
    record status
    PubMed - indexed for MEDLINE
    schema version
    1.0
    source url
    https://pubmed.ncbi.nlm.nih.gov/32888452/
    title
    Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial.

    Preserved source evidence · Not medical advice